Vulvovaginal Candidiasis Treatment Market Size, Demand, Growth, Challenges and Future Trends
Vulvovaginal Candidiasis Treatment Market Size- By Drug Class, By Route of Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2032
| Published: Dec-2022 | Report ID: PHAR2214 | Pages: 1 - 239 | Formats*: |
| Category : Pharmaceutical | |||
Vulvovaginal Candidiasis Treatment Market Introduction and Overview
According to SPER Market Research, the Global Vulvovaginal Candidiasis Treatment Market is estimated to reach USD 1.62 billion by 2032 with a CAGR of 4.61%.
The report includes an in-depth analysis of the Global Vulvovaginal Candidiasis Treatment Market, including market size and trends, product mix, applications, and supplier analysis. Treatment for vulvovaginal candidiasis mostly consists of antifungal drugs, which can be taken orally or as topical creams. Healthcare providers frequently suggest over-the-counter antifungal creams like clotrimazole and miconazole or prescription oral drugs like fluconazole. By getting rid of the extra yeast, these antifungal medications relieve painful symptoms like itching. Known medically as candidal vaginitis or candidal vulvovaginitis, vaginal yeast infections are a common fungal illness. Symptoms of the infection include swelling, rashes, redness, and itching, as well as burning or discomfort during urination or sexual activity. The most common cause of fungal infections in humans is Candida albicans. The most frequent cause of fungal urinary tract infections (UTIs) is Candida species. Candida UTIs can develop in the lower urinary tract or, in rare circumstances, even reach the kidneys. Fluconazole, an antifungal medication, has several applications. The incidence of VVC has surged as a result of rising diabetes occurrences and people's recurrent use of antibiotics.
- June 2021: In June 2021, Scynexis Inc. said that it was conducting Phase 3 clinical studies for IBREXAFUNGERP and Fluconazole tablets. A Phase 3 clinical trial was carried out at several locations for this study. This research compares the safety and efficacy of oral ibrexafungerp (formerly known as "SCY-078") versus a placebo in a randomized, double-blind fashion. The study focuses on female volunteers with recurrent vulvovaginal candidiasis (RVVC) who are 12 years of age or older.
- September 2021: In September 2021, Ege University announced a study of the Phase 3 clinical trials for Gynomax® XL Vaginal Ovule and EVEGYN A. This multicenter, randomized study assessed the safety and effectiveness of Gynomax® XL ovule in treating trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis, and mixed vaginal infections.
Market Opportunities and Challenges
Candal vaginitis, often known as candidal vulvovaginitis (CVV), is the usual term for vaginal yeast infection. The number of instances of yeast infections has increased due to an increase in the worldwide burden of many illnesses, including cancer, neurological, gastrointestinal, and cardiovascular disorders. This has also increased the use of broad-spectrum antibiotics. The need for bacterial vulvovaginal candidiasis therapy is being driven by the quick rise in the worldwide illness burden, the growing incidence of hospital-acquired infections, and the growing need for improved treatment alternatives. Significant potential for the treatment of vulvovaginal candidiasis are also being created by the availability of pharmaceutical medications, the development of substantial technical developments in the biopharmaceutical industry, and the rising healthcare infrastructure in developing nations. Unawareness of Treatment Options for Vulvovaginal Candidiasis Despite the wide range of applications for vulvovaginal candidiasis treatments, the market is expected to face some challenges in its growth throughout the projection period.The expansion of the industry may be restricted by the lack of knowledge among individuals in emerging nations. Furthermore, the market is anticipated to be constrained by the lack of familiarity with sophisticated technologies and the high cost of diagnostic and treatment procedures
Market Competitive Landscape
There are several well-known competitors fighting for market share in the fiercely competitive vulvovaginal candidiasis treatment industry. Major players in the industry include producers of natural products, generic medicine makers, and pharmaceutical behemoths. To increase their market share, these companies concentrate on product launches, mergers and acquisitions, and research and development initiatives. Furthermore, strategic alliances and partnerships with healthcare providers help them broaden their product offerings and geographic scope. Key players are Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Basilea Pharmaceuticals Ltd., Cadila Pharmaceuticals, Dr Reddy’s Laboratories Ltd., Grupo Ferrer Internacional S.A, Glenmark Pharmaceuticals Ltd., Zydus Cadila.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Type, By Drug Class, By Route of Administration, By Distribution Channel. |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe |
| Companies Covered | Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Basilea Pharmaceuticals Ltd., Cadila Pharmaceuticals, Dr Reddy’s Laboratories Ltd., Grupo Ferrer Internacional S.A, Glenmark Pharmaceuticals Ltd., Zydus Cadila |
COVID-19 Impact on Global Vulvovaginal Candidiasis Treatment Market
The market for vulvovaginal candidiasis treatments was affected by the COVID-19 pandemic in many ways. Prescription medicine availability was impacted by supply chain and healthcare resource interruptions, even as the demand for over-the-counter antifungal treatments grew due to the growing emphasis on personal cleanliness and self-care practices. During the epidemic, telemedicine and remote consultations became practical choices for people in need of guidance and medication. Because of all these factors, the market for vulvovaginal candidiasis rebounded swiftly from the first quarter of covid and is expected to continue growing.
Key Target Audience:
- Patients with Recurrent Infections
- Healthcare Providers
- Pharmacies and Pharmacists
- Health Insurance Companies
- Online Health Communities
- Telehealth Providers
- Medical Researchers and Academics
- Pharmaceuticals Companies
- Regulatory Bodies
- Public Health Organizations
Our in-depth analysis of the Vulvovaginal Candidiasis Treatment Market includes the following segments:
| By Type: |
|
| By Drug Class: |
|
| By Route of Administration: |
|
| By Distribution Channel: |
|
Key Topics Covered in the Report:
- Global Vulvovaginal Candidiasis Treatment Market Size (FY’2022-FY’2032)
- Overview of Global Vulvovaginal Candidiasis Treatment Market
- Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Type (Acute Vulvovaginal Candidiasis, Recurrent Vulvovaginal Candidiasis, Severe Vulvovaginal Candidiasis, Non-Albicans Vulvovaginal Candidiasis.)
- Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others).
- Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Route of Administration (Oral, Intravenous, Topical)
- Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Distributional Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
- Statistical Snap of Global Vulvovaginal Candidiasis Treatment Market
- Expansion Analysis of Global Vulvovaginal Candidiasis Treatment Market
- Problems and Obstacles in Global Vulvovaginal Candidiasis Treatment Market
- Competitive Landscape in the Global Vulvovaginal Candidiasis Treatment Market
- Impact of COVID-19 and Demonetization on Global Vulvovaginal Candidiasis Treatment Market
- Details on Current Investment in Global Vulvovaginal Candidiasis Treatment Market
- Competitive Analysis of Global Vulvovaginal Candidiasis Treatment Market
- Prominent Players in the Global Vulvovaginal Candidiasis Treatment Market
- SWOT Analysis of Global Vulvovaginal Candidiasis Treatment Market
- Global Vulvovaginal Candidiasis Treatment Market Future Outlook and Projections (FY’2022-FY’2032)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Global Vulvovaginal Candidiasis Treatment Market.
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Vulvovaginal Candidiasis Treatment Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Vulvovaginal Candidiasis Treatment Market
7. Global Vulvovaginal Candidiasis Treatment Market, By Type (USD Million) 2019-2032
7.1. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Type, 2019-20257.2. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Type, 2026-20327.3. Acute Vulvovaginal Candidiasis7.4. Recurrent Vulvovaginal Candidiasis7.5. Severe Vulvovaginal Candidiasis7.6. Non-Albicans Vulvovaginal Candidiasis
8. Global Vulvovaginal Candidiasis Treatment Market, By Drug Class (USD Million)2019-2032
8.1. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Drug Class, 2019-20258.2. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Drug Class, 2026-20328.3. Clotrimazole8.4. Nystatin8.5. Fluconazole8.6. Ketoconazole8.7. Terbinafine8.8. Terconazole8.9. Others
9. Global Vulvovaginal Candidiasis Treatment Market, By Route of Administration(USD Million)2019-2032
9.1. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Route of Administration, 2019-20259.2. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Route of Administration, 2026-20329.3. Oral9.4. Intravenous9.5. Topical
10. Global Vulvovaginal Candidiasis Treatment Market, By Distribution Channel (USD Million)2019-2032
10.1. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Distribution Channel, 2019-202510.2. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Distribution Channel, 2026-203210.3. Hospital Pharmacy10.4. Retail Pharmacy10.5. Online Pharmacy
11. Global Vulvovaginal Candidiasis Treatment Market Forecast, 2019-2032 (USD Million)
11.1. Global Vulvovaginal Candidiasis Treatment Market Size and Market Share
12. Global Vulvovaginal Candidiasis Treatment Market, By Region, 2019-2032 (USD Million)
12.1. Global Vulvovaginal Candidiasis Treatment Market Size and Market Share By Region (2019-2025)12.2. Global Vulvovaginal Candidiasis Treatment Market Size and Market Share By Region (2026-2032)12.3. Asia-Pacific12.3.1. Australia12.3.2. China12.3.3. India12.3.4. Japan12.3.5. South Korea12.3.6. Rest of Asia-Pacific12.4. Europe12.4.1. France12.4.2. Germany12.4.3. Italy12.4.4. Spain12.4.5. United Kingdom12.4.6. Rest of Europe12.5. Middle East and Africa12.5.1. Kingdom of Saudi Arabia12.5.2. United Arab Emirates12.5.3. Qatar12.5.4. South Africa12.5.5. Egypt12.5.6. Morocco12.5.7. Nigeria12.5.8. Rest of Middle East & Africa12.6. North America12.6.1. Canada12.6.2. Mexico12.6.3. United States12.7. Latin America12.7.1. Argentina12.7.2. Brazil12.7.3. Rest of Latin America
13. Company Profile
13.1. Alembic Pharmaceuticals Limited13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments13.2. Accord Healthcare Ltd.13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments13.3. Aurobindo Pharma Limited13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments13.4. Bristol-Myers Squibb Company13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments13.5. Basilea Pharmaceuticals Ltd.13.5.1. Company details13.5.2. Financial outlook13.5.3. Product summary13.5.4. Recent developments13.6. Cadila Pharmaceuticals13.6.1. Company details13.6.2. Financial outlook13.6.3. Product summary13.6.4. Recent developments13.7. Dr Reddy’s Laboratories Ltd.13.7.1. Company details13.7.2. Financial outlook13.7.3. Product summary13.7.4. Recent developments13.8. Grupo Ferrer Internacional S.A13.8.1. Company details13.8.2. Financial outlook13.8.3. Product summary13.8.4. Recent developments13.9. Glenmark Pharmaceuticals Ltd.13.9.1. Company details13.9.2. Financial outlook13.9.3. Product summary13.9.4. Recent developments13.10. Zydus Cadila13.10.1. Company details13.10.2. Financial outlook13.10.3. Product summary13.10.4. Recent developments13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
The Vulvovaginal Candidiasis Treatment Market grew in market size from 2021. The Market is expected to reach USD 1.62 billion by 2032, at a CAGR of 4.61% during the forecast period.
The Vulvovaginal Candidiasis Treatment Market CAGR of 4.61% during the forecast period.
You can get the sample pages by clicking the link -Click Here
The Vulvovaginal Candidiasis Treatment Market size is USD 1.62 billion from 2022 to 2032.
The Vulvovaginal Candidiasis Treatment Market segment is Covered By Drug Class, By Route of Administration, By Distribution Channel.
The North America and Europe region is anticipated to have the highest market share in the Vulvovaginal Candidiasis Treatment Market.
The key players in the market include Companies Covered Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Basilea Pharmaceuticals Ltd., Cadila Pharmaceuticals, Dr Reddy’s Laboratories Ltd., Grupo Ferrer Internacional S.A, Glenmark Pharmaceuticals Ltd., Zydus Cadila.
The most common cause of fungal infections in humans is Candida albicans. The most frequent cause of fungal urinary tract infections (UTIs) is Candida species.
The Vulvovaginal Candidiasis Treatment Market is projected to reach USD 1.62 billion by 2032, growing at a CAGR of 4.61% during the forecast period.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
